Dossier
Biocytogen Pharmaceuticals
Coverage of Biocytogen Pharmaceuticals in the Nexus archive.
- Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals
Mainland China institutional fund managers have increased investments in Hong Kong-listed biotech stocks due to attractive valuations and rising cross-border licensing deals. E Fund Management acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing additional shares.
- Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals
Mainland Chinese institutional fund managers have increased investments in Hong Kong-listed biotechnology stocks due to attractive valuations and a surge in cross-border licensing deals. E Fund Management, China's largest mutual fund manager, acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing 91,500 shares at HK$46.90 each.